BCDA — Biocardia Inc
NASDAQ · Healthcare · Biotechnology
$1.12
+$0.02 (+1.79%)
Biocardia Inc (BCDA) is a biotechnology company listed on NASDAQ. It is led by Peter A. Altman Ph.D., based in 320 Soquel Way, Sunnyvale, CA, United States, 94085, with about 17 employees. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Net income was -$1.5M. BCDA currently screens at market cap $14.4M.
Use this BCDA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCDA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCDA SEC filings page. Lician reads the product cache first so this HTML stays unique to Biocardia Inc even when a live quote feed is slow.
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
BCDA Key Statistics
Market Cap
$14.39M
Volume
346,868
Previous Close
$1.06
Day Range
$1.02 – $1.14
P/B Ratio
12.35
EPS
$0.00
Revenue
$0.00
Net Income
-$7.95M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
17
BCDA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.95M | -$11.57M | -$11.91M | -$12.62M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$3.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.37M
Operating Cash Flow
-$8.03M
Free Cash Flow
$0.00
Biocardia Inc Company Information
- CEO, President & Director
- Peter A. Altman Ph.D.
- Headquarters
- 320 Soquel Way, Sunnyvale, CA, United States, 94085
- Website
- www.biocardia.com
- Phone
- 650 226 0120
- IPO / Founded
- 2008-03-14
- Sector
- Healthcare
- Industry
- Biotechnology